SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DAVID who wrote (8308)5/21/1998 9:40:00 PM
From: VLAD  Read Replies (1) of 23519
 
DAVID,

Thank you for the review. I think the most important part of this meeting was your question on the potential buy out. If the answer was NO then I would expect a NO. A NO COMMENT to me translates to something like: We are currently negotiating a potential buy out but will not comment until the bottom line is signed. My hunch is that Astra or Johnson and Johnson will be buying out Vivus in the $20 to $25 range some time before the end of this summer. Astra is a cash cow and has mentioned an interest in aquisitions. Both J&J and Astra would have a lot to gain by owning this company.

The shorts better wake up and smell the coffee before they end up losing $10 to $15 per share on their positions. Short interest to be published on the 27th.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News